肾损伤预防试验设计的患者偏好与优先事项:共识研讨会的发现
为设计西司他丁预防肾毒性急性肾损伤的临床试验,召开共识研讨会纳入11例患者和2例照护者。采用改良名义组技术,围绕知情同意与招募、干预实施、试验结局三个主题讨论并投票。患者优先选择技术辅助预筛和家属参与知情同意,优先便于干预实施和复诊的措施,并将肾脏相关及其他临床结局(如急性肾损伤、慢性肾脏病、心血管事件)列为最重要结局。结果将直接用于制定西司他丁预防肾毒性急性肾损伤的试验方案。
要点
- 患者与照护者在知情同意与招募方面优先选择技术辅助预筛和家属参与知情同意过程。
- 在干预实施方面,参与者优先选择便于试验干预给药和复诊的措施。
- 在试验结局方面,参与者将肾脏相关及其他临床结局(如急性肾损伤、慢性肾脏病、心血管事件)列为最重要结局。
- 共13人参与研讨会(11例患者、2例照护者),采用改良名义组技术进行讨论和投票。
- 转录分析揭示了照护团队和家庭参与试验相关决策、安慰剂分组的影响以及急性肾损伤和危重病经历的影响。
适用人群与场景
- 有急性肾损伤、慢性肾脏病或急性肾损伤危险因素(如重症监护住院)亲身经历的成人及其照护者。
研究设计与关键结果
- 采用改良名义组技术召开共识研讨会,纳入13人(11例患者、2例照护者),围绕知情同意与招募、干预实施、试验结局三个主题进行讨论和投票,转录采用常规内容分析归纳分析。
- 知情同意与招募方面,参与者优先选择技术辅助预筛和家属参与知情同意过程。
- 干预实施方面,参与者优先选择便于试验干预给药和复诊的措施。
- 试验结局方面,参与者将肾脏相关及其他临床结局(如急性肾损伤、慢性肾脏病、心血管事件)列为最重要结局。
- 转录分析揭示了照护团队和家庭参与试验相关决策、安慰剂分组的影响以及参与者急性肾损伤和危重病经历的影响。
证据类型、等级与局限
- 证据类型:共识研讨会(改良名义组技术)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,研讨会的发现将直接用于制定西司他丁预防肾毒性急性肾损伤的临床试验方案,并可帮助他人以患者为中心的方法设计急性肾损伤试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
KEY POINTS: For AKI prevention trial recruitment, patients prioritized technology enabled prescreening and involvement of family members in the consent process. For trial intervention delivery, participants prioritized measures to facilitate ease of trial intervention administration and return visits. For AKI prevention trial outcomes, patient participants identified effects on kidney-related and other clinical outcomes as top priorities.
BACKGROUND: High-quality clinical trials are needed to establish the efficacy and safety of novel therapies for AKI prevention. In this consensus workshop, we identified patient and caregiver priorities for recruitment, intervention delivery, and outcomes of a clinical trial of cilastatin to prevent nephrotoxic AKI.
METHODS: We included adults with lived experience of AKI, CKD, or risk factors of AKI (e.g., critical care hospitalization) and their caregivers. Using a modified nominal group technique approach, we conducted a series of hybrid in-person/virtual discussions covering three clinical trial topic areas: (1) consent and recruitment, (2) intervention delivery, and (3) trial outcomes. Participants voted on their top preferences in each topic area, and discussion transcripts were analyzed inductively using conventional content analysis.
RESULTS: Thirteen individuals (11 patients, two caregivers) participated in the workshop. For consent and recruitment, participants prioritized technology enabled prescreening and involvement of family members in the consent process. For intervention delivery, participants prioritized measures to facilitate ease of intervention administration and return visits. For trial outcomes, participants identified kidney-related and other clinical outcomes (e.g., AKI, CKD, cardiovascular events) as top priorities. Analysis of transcripts provided insight into care team and family involvement in trial-related decisions, implications of allocation to a placebo arm, and impact of participants' experiences of AKI and critical illness.
CONCLUSIONS: Findings from our workshop will directly inform development of a clinical trial protocol of cilastatin for nephrotoxic AKI prevention and can assist others in patient-centered approaches to AKI trial design.
参考来源
- Elliott MJ, Fiest KM, Love S, et al. Patient Preferences and Priorities for the Design of an Acute Kidney Injury Prevention Trial: Findings from a Consensus Workshop. Kidney360. 2024. PMID: 39146029. doi:10.34067/KID.0000000000000554
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。